

Designing multi-arm multi-stage adaptive trials for neuroprotection in progressive multiple sclerosis

Vivien Li*, Baptiste Leurent* (co-primary authors)

Frederik Barkhof, Marie Braisher, Fay Cafferty, Olga Ciccarelli, Arman Eshaghi, Emma Gray, Jennifer Nicholas, Mahesh Parmar, Guy Peryer, Jenny Robertson, Nigel Stallard, James Wason, Jeremy Chataway

Statistical analysis performed by: Baptiste Leurent, Fay Cafferty, Jennifer Nicholas, Nigel Stallard, James Wason

ABSTRACT

Progressive multiple sclerosis (PMS) is a significant health problem with few treatments shown to slow disability progression. One challenge has been efficiently testing the pipeline of candidate therapies from preclinical studies in clinical trials. Multi-arm multi-stage (MAMS) platform trials may accelerate evaluation of new therapies compared to traditional sequential clinical trials. We describe a MAMS design in PMS, focusing on selection of interim and final outcome measures, sample size and statistical considerations.

The UK MS Society Expert Consortium for Progression in MS Clinical Trials reviewed recent phase II and III PMS trials to inform interim and final outcome selection and design parameters. Simulations were performed to evaluate trial operating characteristics under different treatment effect, recruitment rate and sample size assumptions. People with MS formed a Patient and Public Involvement group and contributed to the trial design ensuring it would meet the needs of the MS community.

The proposed design evaluates three experimental arms compared to a common standard of care arm in two stages. Stage 1 (interim) outcome will be whole brain atrophy on MRI at 18 months, assessed for 123 participants per arm. Treatments with sufficient evidence for slowing brain atrophy will continue to the second stage. The stage 2 (final) outcome will be time to six-month confirmed disability progression, based on a composite clinical score comprising the Expanded Disability Status Score, Timed 25-Foot Walk and 9-Hole Peg Test. To detect a hazard ratio of 0.75 for this primary final outcome with 90% power, 600 participants per arm are required. Assuming one treatment progresses to stage 2, the trial will recruit around 1,900 participants and last around 6 years. This is approximately two-thirds the size and half the time of separate two-arm phase II and III trials.

The proposed MAMS trial design will substantially reduce duration and sample size compared to traditional clinical trials, accelerating discovery of effective treatment for PMS. The design was also well-received by people with MS. The practical and statistical principles of MAMS trial design may be applicable to other neurodegenerative conditions to facilitate efficient testing of new therapies.

INTRODUCTION

Progressive multiple sclerosis (PMS) is a significant health problem worldwide¹ and has considerable financial costs for healthcare systems, patients and their caregivers, with costs increasing at higher levels of disability²⁻⁴. Despite extensive efforts, there are few proven therapies for PMS. Compared to the predominantly inflammatory pathology in relapsing MS targeted by current treatments, the neurodegenerative processes driving progression in PMS are complex and less well-defined^{5,6}. There is a pipeline of candidate therapies from preclinical studies, but the challenge is testing them efficiently in clinical trials with appropriate outcome measures to determine whether they can successfully slow disability progression.

One potential avenue is improving efficiency of trials by incorporating adaptive elements in a multi-arm multi-stage (MAMS) platform design. MAMS trials aim to evaluate multiple experimental arms and seamlessly integrate traditional phase II and III evaluations into a single trial. They have been successful in accelerating evaluation of therapies and changing practice in other disease settings, such as cancer⁷ and infectious diseases⁸. They are also increasingly being considered for neurological conditions such as Alzheimer's disease⁹, Parkinson's disease¹⁰ and motor neuron disease^{11,12}. These neurodegenerative conditions share commonalities with PMS, where there is a marked translational gap between the relative abundance of early phase trials stemming from increased understanding of disease pathobiology, and lack of positive phase III trials leading to disease-modifying treatments.

Adaptive MAMS platform designs offer flexible features which can provide efficiencies at various levels¹³. These include simultaneous evaluation of multiple treatments against a common standard of care reducing both time and numbers of patients required; the ability to add new treatments as they become relevant, avoiding lengthy set-up times for multiple trials; dropping treatments that are not showing sufficient promise allowing redirection of resources; and incorporation of the traditional separate phase II and III evaluations within a single protocol with seamless transitions.

With the aim of designing a MAMS trial in PMS, the UK MS Society Expert Consortium for Progression in MS Clinical Trials set up four working groups on outcome measures, trial design, treatment selection and trial infrastructure. Each group included members with relevant expertise and worked closely with the patient and public involvement group throughout the development process. The work of the treatment selection working group on identifying and shortlisting candidate treatments, focusing on licensed drugs that can be repurposed, has been reported elsewhere¹⁴.

This paper describes the work of the trial design and outcome measures working groups. We discuss key elements of the MAMS trial design based on evaluation of three candidate treatments against standard of care in two analysis stages, including selection of the primary interim and final outcomes, sample size and other statistical considerations.

Box 1: Glossary of terms

- Adaptive trial – a trial with scheduled interim analyses to evaluate observed data during the course of the trial, which inform and allow pre-specified changes to be made while maintaining the overall integrity of the trial.
- Platform trial – a long-term trial which evaluates multiple hypotheses. Defined around core elements but allowing for flexibility, such as adding new treatment arms or changing the standard of care.
- Multi-arm multi-stage trial (MAMS) – a trial which tests several interventions simultaneously against a shared contemporaneous control group, with potentially seamless transition from phase II to phase III evaluations.

- Multi-arm multi-stage, platform and adaptive trial – all the above elements combined in the same trial.
- Phase II trials – trials typically involving up to a few hundred participants aiming to demonstrate that the treatment is sufficiently safe and promising, usually demonstrating effect on an intermediary (biological) outcome.
- Phase III trials – trials typically involving some hundreds or thousands of participants aiming to provide definitive clinical evidence of treatment efficacy.
- Stage 1 or interim analysis – analyses performed during the course of the trial at a pre-specified time point to assess for early evidence of activity or futility of a treatment.
- Stage 2 or final analysis – analyses performed at the end of a trial to assess the efficacy of promising treatment(s) based on interim analysis, usually based on relevant clinical outcomes.
- Type I error or alpha – rejecting a true null hypothesis (false positive finding).
- Type II error – accepting a false null hypothesis (false negative finding).
- Power – the probability that a statistical test will reject a false null hypothesis, i.e. probability of detecting a specific difference when it truly exists. It is equal to 1 – type II error rate.

METHODS

Outcome measures

The outcome measures working group comprised individuals with expertise in MS trials, imaging and biomarkers, as well as people with MS with lived experience of the condition. The group reviewed the literature to determine outcome measures relevant to a MAMS trial evaluating predominantly neuroprotective treatments. Individual members submitted proposed outcome measures based on their expertise with final prioritisation of outcomes determined in consensus meetings.

The MAMS design allows distinct interim (stage 1) and final (stage 2) outcomes. The final outcome should be clinically derived and relevant to patients and regulators. The interim outcome serves as an early indicator of whether a treatment is likely to be effective and hence should be continued into the second stage of the trial whilst minimising the likelihood of ceasing truly effective treatments. It should reflect the underlying association between the treatment and the clinical outcome. The absence of effect on the interim outcome should be indicative of the absence of effect on the final outcome, although the converse may not necessarily hold¹⁵.

Trial design

The trial design working group, comprising experts in design and implementation of MAMS trials, statisticians and MS clinicians, was tasked with generating design options for running an efficient, scalable and flexible clinical trial by exploring different scenarios to determine the best design type. The group reviewed data from phase II and III randomised controlled PMS trials from January 1 2009 to January 1 2019 to inform key design parameters for both stage 1 and 2 analyses, such as effect size, and the relationship between the interim and final outcomes.

To assess the statistical operating characteristics of the trial (e.g. type I and type II error rates), we simulated multiple trials with different correlation structures for the treatment effects on stage 1 and stage 2 outcomes, under different treatment effect assumptions. We also modelled the expected trial progress over time, based on different assumptions (such as recruitment rates) and design parameters (such as sample size and treatment stopping rules) to the second stage. Further details of the simulation methods are reported in eAppendix 2 and 3 in the Supplement. To support the design of

the stage 1 analysis we analysed brain atrophy data from the MS-STAT1¹⁶ and ASCEND¹⁷ clinical trials (for full methods see eAppendix 2 in the Supplement). Modelling was conducted in Stata version 15 (StataCorp, TX) and Microsoft Excel 2016.

Patient and Public Involvement

A Patient and Public Involvement (PPI) strategy group was involved since the earliest conception of the project and were members of each of the Expert Consortium working groups. The PPI strategy group included four members of the MS Society's Research Network who have been affected by MS and the MS Society's Public Involvement Officer. They contributed to discussions as the project developed and focused on ensuring that the research would meet the needs of the MS community. Additional workshops attended by a total of 34 people with MS held in three UK locations brought in further expertise of people affected by MS on topics including relevance, feasibility and acceptability of all aspects of the trial design as well as recruitment and engagement strategies.

Data availability

Data not published in this article will be made available by request from any qualified investigator.

REVIEW OF PREVIOUS TRIALS

Our review identified 15 eligible phase II (n=8) and phase III (n=7) randomised trials in PMS (Table 1). The median trial size was 374 participants (range 54 to 1,651) and median follow-up duration was 2 years (range 1 to 4.5 years). Trials included both secondary progressive MS (SPMS) (n=6), primary progressive MS (PPMS) (n=6) and mixed PMS (n=3) patients. Confirmed disability progression on Expanded Disability Status Score (EDSS) was reported in 9 trials at different time intervals ranging from 3 to 6 months, whilst a composite outcome was reported in 4. Two (29%) of the phase III trials (siponimod, ocrelizumab) and 4 (50%) of the phase II trials (ibudilast, lipoic acid, biotin, simvastatin) were positive for their primary endpoints.

PROPOSED MAMS TRIAL DESIGN

Overview

We propose the design of a two-stage MAMS trial in PMS: one interim analysis to examine early evidence of treatment effect (stage 1) and one final confirmatory analysis of efficacy (stage 2). The trial would include four arms in stage 1: one standard of care (control) arm and three experimental arms. Any treatment that is sufficiently promising at the interim analysis will progress to stage 2, which will continue until the required number of events is reached, as represented in Figure 1.

It is expected that in the initial phase of the trial the standard of care arm for most participants will comprise best supportive care. Whilst ocrelizumab and siponimod have been approved for PMS, these treatments are not currently available to or suitable for all patients, in particular non-ambulatory patients, who would be eligible for this proposed trial. If an efficacious therapy is subsequently found, this would then become the standard of care for future participants entering the platform.

The number of experimental arms was informed by feasibility constraints and the treatment selection group's work on number of repurposed therapies ready for clinical testing¹⁴. Participants will be randomised with an equal probability between each of the 4 arms (1:1:1:1 ratio). In a standard multi-arm trial with n experimental arms, the optimal allocation ratio would be $\sqrt{n}:1$ in favour of the control arm. This is because the control participants contribute to each of the pairwise comparison. However, for a MAMS trial this depends on the number of arms continuing into stage 2, which is unknown¹⁸. Unequal allocation would also make the trial less attractive to people with MS, as it results in a lower likelihood of being randomised to an experimental arm.

Choice of stage 2 (final) primary outcome

The classical measurement tool and regulatory standard has been the EDSS¹⁹, used to determine the time to disability progression. Its strengths and limitations are well-documented²⁰ and numerous attempts have been made to evolve it, including using a composite measure based on progression in one or more of three endpoints: 1) increase in EDSS (of ≥ 1 point if baseline EDSS was < 5.5 or ≥ 0.5 points if baseline EDSS was ≥ 5.5), 2) $\geq 20\%$ increase in 9-hole peg test (9HPT), or 3) $\geq 20\%$ increase in timed 25-foot walk (T25FW) (if ambulant)²¹.

Composite measures achieve higher event rates than single measures (eAppendix 1 in the Supplement), which can reduce trial duration and sample size. For example, in the INFORMS phase III trial of fingolimod in PPMS, over 70% of participants had reached progression on the 3-month confirmed disability composite outcome by 3 years, as opposed to 50% based on EDSS alone²². Inclusion of a measure of upper limb function also addresses the PPI group's interest in expanding the traditionally narrow EDSS inclusion criteria to include patients with higher levels of disability, to whom arm function is critical and measures of ambulation less relevant²³.

Based on these considerations, we selected time to 6-month confirmed composite disability progression as the primary outcome for the final (stage 2) analysis. The composite outcome will be measured at baseline and every six months until the end of the follow up. The time to progression will be from randomisation until date of the initial disability progression (if subsequently confirmed). Based on earlier trials (eAppendix 1 in the Supplement), we expect the rate of 6-month confirmed composite disability progression to be around 50% at 3 years.

Choice of stage 1 (interim) primary outcome

Whole brain atrophy on MRI, measured as annualised percentage of brain volume change (PBVC), was selected as the primary interim outcome, based on the initial candidate drugs having primarily neuroprotective mechanisms of action. Brain atrophy reflects underlying neuroaxonal loss, which contributes to accrual of disability in PMS, and has been successfully used as a primary outcome in phase II trials, including the MS-STAT1¹⁶, MS-SMART²⁴ and SPRINT-MS²⁵ studies. Importantly for a multi-stage trial, the treatment effect size on atrophy has been found to correlate with the clinical disability endpoint in a meta-analysis of RRMS trials²⁴.

Methods of measuring PBVC include registration-based techniques (such as Boundary Shift Integral [BSI] and Structural Image Evaluation, using Normalisation, of Atrophy [SIENA]) or brain parenchymal fraction (BPF), which quantify the amount of brain tissue contained within a contour surrounding the entire brain including cerebrospinal fluid²⁶. Some therapies, particularly those with anti-inflammatory effects, can excessively reduce brain volume in the first months (pseudoatrophy)²⁷, so it was recommended to assess PBVC also after at least six months on treatment.

We considered other imaging-based measures including spinal cord atrophy, which contributes to MS disability progression and occurs at a faster rate than brain atrophy²⁸, neurite indices derived from diffusion MRI, which reflect the microstructural changes of axons and dendrites, and magnetisation transfer imaging which reflects demyelination and axonal loss¹⁹. However, technical challenges currently limit widespread implementation and standardisation across multiple centres²⁷. Although biofluid markers such as neurofilament light chain are associated in high concentrations with disability and brain atrophy²⁹, there are mixed findings on whether they are sensitive to treatment and are not ready to be used as primary outcome measures until a validated, standardised, and widely accessible assay is available, with normative values of neurofilaments across age groups. Moreover, there is divergence of their utility in relapsing MS compared to PMS³⁰.

Predicted brain atrophy rate

Nine of the reviewed trials reported a direct measure of change in whole brain volume (eAppendix 2 in the Supplement). Brain atrophy rate varied between 0.4%/year and 0.7%/year in control arms. There was no clear pattern of differences between trials in PPMS or SPMS or by follow-up length. The standard deviation for atrophy rate decreased with increasing follow-up length, ranging from 0.59%/year to 0.78%/year over one year, and 0.37%/year to 0.60%/year over two years.

The predicted standard deviations based on applying our statistical model (eAppendix 2 in the Supplement) to the data from MS-STAT1 and ASCEND is shown in Figure 2. The standard deviation is expected to decrease rapidly with increasing length of follow-up, especially in the first 12 months. After 18-24 months, the reduction in standard deviation becomes much smaller.

Timing of the interim analysis is an important consideration of adaptive designs. It should occur after accruing sufficient participant data to make a reliable decision on continuing or dropping treatment arms, but early enough relative to total trial recruitment to have value in informing adaptation of the trial design³¹. Based on these considerations, PBVC at 18 months' follow-up will be assessed at interim analysis. If pseudoatrophy is present at 6 months, then PBVC between 6 and 24 months' follow-up will be assessed. This choice achieves a balance between reducing variance of the measure, whilst ensuring that the interim analysis was sufficiently timely to make it worthwhile (see below). The standard deviation at this point is predicted to be around 0.55%/year.

Treatment effects on brain atrophy and clinical progression

A key criterion for the stage 1 outcome is the ability to identify treatments expected to be ineffective and also potentially effective in terms of the final (stage 2) outcome. We reviewed trials reporting treatment effect on both brain atrophy rate and clinical progression. Trial results are reported in eAppendix 3 in the Supplement and summarised in Figure 3. There is a negative correlation, indicating that drugs with a stronger effect on reducing brain atrophy in PMS were more effective on clinical outcomes, confirming findings in RRMS²⁶.

Our trial targets a treatment effect of 25% relative reduction in the 6-month confirmed disability progression rate, i.e. a hazard ratio of 0.75. This is a clinically important effect in slowing progression in ambulation, upper limb function or disability, which has been achieved in previous trials³². Assuming 50% of patients experience a disability progression by 3 years in the control arm, a 25% relative reduction would equate to a 12.5% absolute difference (50% control vs 37.5% active treatment).

Based on the review of previous trials, we assumed an effective treatment would reduce the rate of whole brain atrophy by around 0.15%/year, from 0.55%/year to 0.40%/year.

Stage 1 sample size

The sample size for stage 1 analysis was based on pairwise comparisons between whole brain atrophy rate at 18 months between each intervention arm and standard of care. A one-sided test is used for the interim analysis, with a treatment continuing to the second stage if there is evidence in favour of a lower atrophy rate compared to standard of care. We chose 95% power because a priority of the interim analysis is to minimise the chance of stopping an arm when the treatment is genuinely active in slowing brain atrophy (i.e. avoid false negatives). Stage 1 alpha (type I error rate) captures the probability of an ineffective treatment to continue to the second stage. It should be chosen to balance minimising this risk whilst ensuring the timeliness of the interim analysis. Designs were considered with stage 1 alpha between 20% and 50% with the final choice of 35%, representing an achievable sample size and timely interim analysis (see trial timeline). This is in line with other MAMS trials¹⁵, but differs from the 5% commonly used in confirmatory analysis, as the objectives here are different. Assuming a standard deviation of 0.55%/year (see above), 111 observations per arm will allow 95% power to detect a 0.15%/year difference at a one-sided significance level (alpha) of 35%. Allowing for 10% drop-out, 123 participants are needed per arm.

Therefore, we recommended that stage 1 analysis be conducted once 18 months' brain atrophy data are available for 111 participants per arm, with pairwise comparison for each experimental arm compared to the control arm. If the one-sided p-value is below 0.35, then the treatment arm is continued into stage 2.

Stage 2 sample size

The sample size for the stage 2 analysis was based on comparing the time to confirmed-disability progression between each intervention arm to standard of care. For each pairwise comparison, to have 90% stage 2 power to detect a hazard ratio of 0.75 at the two-sided stage 2 significance level of 5% (or equivalently a 2.5% one-sided significance level), 281 progression events are required in the control arm, and 600 participants per arm are needed.

The stage 2 significance level was set at a two-sided 5% level, as in standard confirmatory trials, corresponding to a one-sided level of 0.025. The question of multiplicity (adjusting significance level due to multiple comparisons) has been discussed before in MAMS¹⁸. We aimed to select drugs with different mechanisms which might be viewed as independent evaluations, similar to multiple trials being conducted³³, and therefore did not apply any correction for multiple comparisons. If drugs of similar action are selected (e.g. different doses of the same drug) an appropriate correction (e.g. Dunnett³⁴) should probably be applied. The statistical power in a time-to-event analysis is determined by the number of events. Recruiting 600 participant per arm should be sufficient to observe the required 281 progression events in the control arm in a timely manner. This number of events is anticipated to occur around 18 months after the last participant has been enrolled, assuming a 10% drop-out rate and 50% disability progression rate by 3 years and recruitment rate, as described in eAppendix 5 in the Supplement (see trial timeline).

Trial operating characteristics

We conducted simulations to assess the operating characteristics of the proposed trial design under different scenarios (see eAppendix 4 in the Supplement for methods and full results). Table 2 shows the overall trial characteristics, depending on the number of truly effective treatments at the start of the trial. In all scenarios, the probability to wrongly conclude that one or more treatments are effective (false positive) is below 4%. The chance of correctly concluding that at least one treatment is effective (power) if a single effective drug enters the trial is around 87%, but this increases to above 96% if more than one effective drug enters the trial.

Trial timeline

An important consideration in adaptive trials is to anticipate the possible dynamics of the trial over time, including the relative timing of the interim and final analyses. eAppendix 5 in the Supplement describes the assumptions made, and how the timeline was modelled. Results are summarised in Table 3. Under a 'base-case' scenario of 40 to 50 participants recruited per month and one experimental arm continuing into stage 2, we expect the interim analysis to be conducted after around 3.4 years, and the final analysis after 6.1 years (ranging between 5.7 to 6.6 years depending on different scenarios modelled).

DISCUSSION

MAMS trials have considerable potential in PMS, where there are many candidate therapies, as well as relevant interim outcome measures that have appropriate relationship to final clinical outcomes. We propose here a MAMS trial design which could potentially accelerate the evaluation of new treatments in PMS.

Advantages

The proposed MAMS design leads to efficiencies in both sample size and trial duration compared to traditional separate phase II and III trials of single treatments. A single control arm is used to assess multiple experimental arms and participants recruited in stage 1 seamlessly continue to be included in the stage 2 analysis without additional set-up time in between. This trial is expected to last six to seven years with 1,900 participants, encompassing the stage 1 and 2 evaluations of three initial candidate treatments (Figure 1 and eAppendix 5 in the Supplement).

In comparison, under the traditional approach, around 630 patients would be required in each of three phase II studies to have 90% power with 5% type I error under the same assumptions. If one of these treatments was found to be effective and proceeded to phase III, 1,200 additional participants would be required, totalling 3,090 participants. Separate phase II and III trials of a single treatment would be expected to take more than 10 years, with 3-5 years for the phase II, 5-7 years for phase III, and additional set-up time between the two (Figure 1). For example, evaluation of high dose simvastatin is following a more conventional path with separate phase II (MS-STAT)¹⁶ and phase III (MS-STAT2)³⁵ trials. Recruitment to MS-STAT started in 2011 and MS-STAT2 is expected to be completed by 2025, which corresponds to 14 years overall.

Challenges

Planning and setting up a MAMS adaptive platform trial is considerably more complex than standard phase II and III trials and may take up to 12 to 18 months. In particular, statistical simulations examining different design options, scenarios and parameters are essential to optimise efficiency and

select appropriate trial operating characteristics while preserving the overall integrity of the trial. The initial modest investment in time and resources will be further offset by shorter subsequent setup times for further treatments added to the platform.

As adaptive platform designs are relatively novel in neurodegenerative diseases, there is a perception that regulatory agencies may not immediately accept them as equal to more conventional phase III studies. However, a precedent has been set for regulatory approval of MAMS platform trials in settings such as oncology⁷ and infectious diseases⁸ and our experience in these other disease areas suggests that regulators are becoming more open to, and knowledgeable and indeed welcoming about, such designs.

Patient and public involvement

The PPI group actively participated in the entire trial design process, as well as treatment and outcome measure selection, to ensure the needs of people with MS were being met. For example, it was important, particularly for non-ambulatory people with MS, to include an assessment of upper limb function in the primary efficacy endpoint and proposed secondary outcomes included patient-reported outcome measures of key symptoms such as fatigue. Feedback indicated the trial design was well-received and acceptable, despite being more complex. Perceived advantages included the ability to evaluate multiple candidate treatments and the relatively lower likelihood of randomisation to placebo. If a participant's treatment arm is discontinued after interim analysis, there is the potential opportunity to re-enter the trial in a continuing arm or future trials in the platform. Whilst some expressed concern about the total trial duration, this was offset by the favourable consensus overall regarding potential acceleration of treatment discovery.

Scope and future developments

This article is based on work conducted by the trial design working group and in many senses is an evolution from our work carried out a decade ago³⁶. A programme grant proposal based on activity of all working groups of the UK MS Society's Expert Consortium for Progression in MS was submitted to the UK MS Society in November 2019 and received favourable international peer and lay review. Funding has been awarded to develop the protocol and deliver the first active arms plus standard of care in the MAMS trial platform, with recruitment expected to commence in 2022. Whilst this paper focuses on evaluation of only the first three candidate therapies, the adaptive MAMS platform will allow addition of new treatment arms⁷ and re-randomisation of participants from discontinued arms in the future³⁷. Drugs with predominantly remyelinating potential will likely require additional and alternative endpoints at the interim analysis stage. Further aspects of the trial protocol, for example secondary and exploratory outcomes and recruitment infrastructure, are beyond the scope of this article.

Adaptive platform trials in other neurological disorders

Like PMS, conditions such as Parkinson's disease, Alzheimer's disease and motor neuron disease are increasing in prevalence, have significant impact on patients, carers and healthcare systems and currently have no or few therapies that slow or prevent progression. An improved understanding of disease pathophysiology in recent years has led to a growing pipeline of potential therapeutics. For example, a 2020 review identified 121 agents in 136 phase I to III clinical trials for Alzheimer's disease, with an increasing number of disease-modification treatment candidates over the past five years³⁸. However, these conditions face similar challenges of efficiently translating candidate drugs into effective treatments with many disappointing phase III clinical trial results to date. Various reasons for this have been proposed, including the need to improve trial design^{10,12,39}.

MAMS designs are particularly relevant when there are multiple candidate therapies to be trialled and when a reliable early marker of clinical efficacy is available. MAMS adaptive platform trials have been planned and initiated to accelerate successful drug discovery in these disorders. The Motor Neuron Disease – Systematic Multi-arm Adaptive Randomisation Trial (MND-SMART) will initially test two repurposed drugs against a common placebo¹¹. The Dominantly Inherited Alzheimer’s Network Trials Unit (DIAN-TU) platform trial established in 2012 was a multi-arm trial of two anti-amyloid monoclonal antibodies. Although neither drug met the primary cognitive endpoint⁴⁰, lessons learnt including refinements in participant and outcome measure selection and trial duration have led to several emerging platform trials, such as the AHEAD study evaluating different doses of an anti-A β monoclonal antibody in two phase III clinical trials that respectively use amyloid PET and cognitive testing as the primary outcome measures⁹.

The principles of designing a PMS MAMS trial outlined in this article are relevant to other neurodegenerative conditions, but each condition will present unique considerations and challenges, including selection of biologically and clinically relevant, sensitive and timely interim and final outcome measures, determination of the most appropriate patient population for inclusion and trial duration required to detect a meaningful effect.

CONCLUSION

Here, we propose a design for a MAMS trial in PMS for evaluation of three repurposed neuroprotective drugs compared to standard of care. Although more complex in design, efficiencies in participant numbers and trial duration, as well as the ability to incorporate adaptive elements and continually test newly identified treatments through an ongoing platform, make this approach more likely to succeed in finding effective therapies that target disability progression in PMS in a timely manner.

ACKNOWLEDGEMENTS

Susan Scott, Research Network member of the UK Multiple Sclerosis Society, provided advice during the trial design process and reviewed the manuscript.

This work was funded by a project grant from the Multiple Sclerosis Society. It was supported (in part) by (an) award(s) from the International Progressive MS Alliance, award reference number PA-1412-02420. We acknowledge the support of the ACORD collaboration: A Collaboration Of groups developing, Running and reporting multi-arm multi-stage trials in neurodegenerative Diseases (<https://www.mrcctu.ucl.ac.uk/studies/all-studies/a/acord/>).

REFERENCES

1. MS International Federation. *Atlas of MS 3rd Edition.*; 2020. Accessed September 3, 2021. <https://www.msif.org/resource/atlas-of-ms-2020/>
2. Karampampa K, Gustavsson A, Miltenburger C, Tyas D. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from the United Kingdom. *Mult Scler.* 2012;18(2_suppl):41-45. doi:10.1177/1352458512441566e
3. Thompson A, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: Results for the United Kingdom. *Mult Scler.* 2017;23(2_suppl):204-216. doi:10.1177/1352458517708687
4. Chataway J, Murphy N, Khurana V, Schofield H, Findlay J, Adlard N. Secondary progressive multiple sclerosis: a systematic review of costs and health state utilities. *Current Medical Research and Opinion.* 2021;37(6):995-1004. doi:10.1080/03007995.2021.1904860
5. Ontaneda D, Fox RJ, Chataway J. Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. *The Lancet Neurology.* 2015;14(2):208-223. doi:10.1016/S1474-4422(14)70264-9
6. Pardini M, Cutter G, Sormani MP. Clinical trial design for progressive MS trials. *Mult Scler.* 2017;23(12):1642-1648. doi:10.1177/1352458517729461
7. Sydes MR, Parmar MK, Mason MD, et al. Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. *Trials.* 2012;13(1):168. doi:10.1186/1745-6215-13-168
8. Phillips PPJ, Gillespie SH, Boeree M, et al. Innovative Trial Designs Are Practical Solutions for Improving the Treatment of Tuberculosis. *The Journal of Infectious Diseases.* 2012;205(suppl_2):S250-S257. doi:10.1093/infdis/jis041
9. Aisen PS, Bateman RJ, Carrillo M, et al. Platform Trials to Expedite Drug Development in Alzheimer's Disease: A Report from the EU/US CTAD Task Force. *J Prev Alzheimers Dis.* 2021;8(3):306-312. doi:10.14283/jpad.2021.21
10. Zeissler ML, Li V, Parmar MKB, Carroll CB. Is It Possible to Conduct a Multi-Arm Multi-Stage Platform Trial in Parkinson's Disease: Lessons Learned from Other Neurodegenerative Disorders and Cancer. *JPD.* 2020;10(2):413-428. doi:10.3233/JPD-191856
11. University of Edinburgh. *Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial.* clinicaltrials.gov; 2021. Accessed September 4, 2021. <https://clinicaltrials.gov/ct2/show/NCT04302870>
12. Kiernan MC, Vucic S, Talbot K, et al. Improving clinical trial outcomes in amyotrophic lateral sclerosis. *Nat Rev Neurol.* 2021;17(2):104-118. doi:10.1038/s41582-020-00434-z
13. Parmar MK, Sydes MR, Cafferty FH, et al. Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols. *Clinical Trials.* 2017;14(5):451-461. doi:10.1177/1740774517725697

14. Cunniffe N, Vuong KA, Ainslie D, et al. Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis. *J Neurol Neurosurg Psychiatry*. 2021;92(3):295-302. doi:10.1136/jnnp-2020-324286
15. Sydes MR, Parmar MKB, James ND, et al. Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial. *Trials*. 2009;10:39. doi:10.1186/1745-6215-10-39
16. Chataway J, Schuerer N, Alsanousi A, et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. *The Lancet*. 2014;383(9936):2213-2221. doi:10.1016/S0140-6736(13)62242-4
17. Kapoor R, Ho PR, Campbell N, et al. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. *The Lancet Neurology*. 2018;17(5):405-415. doi:10.1016/S1474-4422(18)30069-3
18. Wason J, Magirr D, Law M, Jaki T. Some recommendations for multi-arm multi-stage trials. *Stat Methods Med Res*. 2016;25(2):716-727. doi:10.1177/0962280212465498
19. Tur C, Moccia M, Barkhof F, et al. Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting. *Nat Rev Neurol*. 2018;14(2):75-93. doi:10.1038/nrneurol.2017.171
20. Meyer-Moock S, Feng YS, Maeurer M, Dippel FW, Kohlmann T. Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis. *BMC Neurol*. 2014;14(1):58. doi:10.1186/1471-2377-14-58
21. Cadavid D, Cohen JA, Freedman MS, et al. The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. *Mult Scler*. 2017;23(1):94-105. doi:10.1177/1352458516638941
22. Lublin F, Miller DH, Freedman MS, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. *The Lancet*. 2016;387(10023):1075-1084. doi:10.1016/S0140-6736(15)01314-8
23. Queen Mary University of London. *ChariotMS - A National (UK) Phase IIb, Multi-Centre, Randomised, Double-Blind, Placebo Controlled (1:1) Efficacy Trial With Cost-Utility Analysis of Cladribine Tablets (3.5mg/Kg Over Two Years) in People With Advanced Multiple Sclerosis. Is Cladribine Superior to Placebo in Protecting Upper Limb Function?* clinicaltrials.gov; 2021. Accessed September 30, 2021. <https://clinicaltrials.gov/ct2/show/NCT04695080>
24. Chataway J, De Angelis F, Connick P, et al. Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial. *The Lancet Neurology*. 2020;19(3):214-225. doi:10.1016/S1474-4422(19)30485-5
25. Fox RJ, Coffey CS, Conwit R, et al. Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. *N Engl J Med*. 2018;379(9):846-855. doi:10.1056/NEJMoa1803583

26. Sormani MP, Arnold DL, De Stefano N. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. *Annals of Neurology*. 2014;75(1):43-49. doi:10.1002/ana.24018
27. Moccia M, de Stefano N, Barkhof F. Imaging outcome measures for progressive multiple sclerosis trials. *Mult Scler*. 2017;23(12):1614-1626. doi:10.1177/1352458517729456
28. Moccia M, Prados F, Filippi M, et al. Longitudinal spinal cord atrophy in multiple sclerosis using the generalized boundary shift integral. *Ann Neurol*. 2019;86(5):704-713. doi:10.1002/ana.25571
29. Barro C, Benkert P, Disanto G, et al. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. *Brain*. 2018;141(8):2382-2391. doi:10.1093/brain/awy154
30. Williams T, Zetterberg H, Chataway J. Neurofilaments in progressive multiple sclerosis: a systematic review. *J Neurol*. 2021;268(9):3212-3222. doi:10.1007/s00415-020-09917-x
31. Wason JMS, Brocklehurst P, Yap C. When to keep it simple – adaptive designs are not always useful. *BMC Medicine*. 2019;17(1):152. doi:10.1186/s12916-019-1391-9
32. Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. *The Lancet*. 2018;391(10127):1263-1273. doi:10.1016/S0140-6736(18)30475-6
33. Freidlin B, Korn EL, Gray R, Martin A. Multi-arm clinical trials of new agents: some design considerations. *Clin Cancer Res*. 2008;14(14):4368-4371. doi:10.1158/1078-0432.CCR-08-0325
34. Dunnett CW. A Multiple Comparison Procedure for Comparing Several Treatments with a Control. *Journal of the American Statistical Association*. 1955;50(272):1096-1121. doi:10.1080/01621459.1955.10501294
35. University College, London. *A Phase 3 Randomised, Double Blind, Clinical Trial Investigating the Effectiveness of Repurposed Simvastatin Compared to Placebo, in Secondary Progressive Multiple Sclerosis, in Slowing the Progression of Disability*. clinicaltrials.gov; 2018. Accessed July 1, 2021. <https://clinicaltrials.gov/ct2/show/NCT03387670>
36. Chataway J, Nicholas R, Todd S, et al. A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis. *Mult Scler*. 2011;17(1):81-88. doi:10.1177/1352458510382129
37. Kahan BC, Forbes AB, Doré CJ, Morris TP. A re-randomisation design for clinical trials. *BMC Med Res Methodol*. 2015;15(1):96. doi:10.1186/s12874-015-0082-2
38. Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer's disease drug development pipeline: 2020. *Alzheimer's & Dementia: Translational Research & Clinical Interventions*. 2020;6(1):e12050. doi:10.1002/trc2.12050
39. Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? *The Lancet Neurology*. 2014;13(11):1127-1138. doi:10.1016/S1474-4422(14)70129-2

40. Salloway S, Farlow M, McDade E, et al. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. *Nat Med*. 2021;27(7):1187-1196. doi:10.1038/s41591-021-01369-8
41. Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. *N Engl J Med*. 2016;376(3):209-220. doi:10.1056/NEJMoa1606468
42. Brochet B, Deloire MSA, Perez P, et al. Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis. Friede T, ed. *PLoS ONE*. 2017;12(1):e0168834. doi:10.1371/journal.pone.0168834
43. Zajicek J, Ball S, Wright D, et al. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial. *The Lancet Neurology*. 2013;12(9):857-865. doi:10.1016/S1474-4422(13)70159-5
44. Hawker K, O'Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. *Ann Neurol*. 2009;66(4):460-471. doi:10.1002/ana.21867
45. Kapoor R, Furby J, Hayton T, et al. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. *The Lancet Neurology*. 2010;9(7):681-688. doi:10.1016/S1474-4422(10)70131-9
46. Spain R, Powers K, Murchison C, et al. Lipoic acid in secondary progressive MS. *Neurol Neuroimmunol Neuroinflamm*. 2017;4(5):e374. doi:10.1212/NXI.0000000000000374
47. Tourbah A, Lebrun-Frenay C, Edan G, et al. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. *Mult Scler*. 2016;22(13):1719-1731. doi:10.1177/1352458516667568
48. Kosa P, Wu T, Phillips J, et al. Idebenone does not inhibit disability progression in primary progressive MS. *Multiple Sclerosis and Related Disorders*. 2020;45:102434. doi:10.1016/j.msard.2020.102434
49. Giovannoni G, Knappertz V, Steinerman JR, et al. A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis. *Neurology*. 2020;95(8):e1027-e1040. doi:10.1212/WNL.00000000000010284

TABLES

Table 1 Description of PMS randomised controlled trials included in the review.

Trial (name, drug assessed)	Participants	PPMS /SPMS	Trial duration	Data on confirmed progression ^a	Data on whole brain atrophy ^b	Reference
Phase III						
EXPAND (Siponimod)	1651	SPMS	36 months	EDSS 3m EDSS 6m	Direct change	32
ASCEND (Natalizumab)	887	SPMS	36 months	Composite 6m	Direct change	17
ORATORIO (Ocrelizumab)	732	PPMS	Up to 50 months	EDSS 3m EDSS 6m Composite 3m Composite 6m	Direct change	41
INFORMS (Fingolimod)	823	PPMS	Up to 60 months	EDSS 3m Composite 3m	Direct change	22
PROMESS (Cyclophosphamide)	138	SPMS	24 months	EDSS 4m	None	42
CUPID (Dronabinol)	498	PPMS /SPMS	36 months	EDSS 6m	Direct change	43
OLYMPUS (Rituximab)	439	PPMS	24 months	EDSS 3m	Indirect change	44
Phase II						
Lamotrigine	120	PPMS	24 months	None	Direct change	45
SPRINT-MS (Ibudilast)	255	PPMS /SPMS	24 months	EDSS 5m	Brain parenchymal fraction	25
Lipoic acid	54	SPMS	24 months	None	Direct change	46
MS-SPI (Biotin)	154	PPMS /SPMS	12 months	EDSS 3m	None	47
MS-STAT1 (Simvastatin)	140	SPMS	24 months	EDSS unconfirmed	Direct change	16
IPPoMS (Idebenone)	85	PPMS	24 months	Composite 6m	Unclear	48
MS-SMART (Amiloride, riluzole and fluoxetine)	440	SPMS	24 months	None	Direct change	24
ARPEGGIO (Laquinimod)	374	PPMS	12 months	EDSS 3m	Unclear	49

Abbreviations: PPMS – primary progressive multiple sclerosis; SPMS – secondary progressive multiple sclerosis; EDSS – Expanded Disability Status Scale

^a Xm – disability progression confirmed after X months.

^b Direct change – registration-based techniques, such as Boundary Shift Integral (BS) and Structural Image Evaluation, using Normalisation, of Atrophy (SIENA)

Table 2 Trial operating characteristics according to number of effective treatments entering the trial.

		Number of (truly) effective treatments at start of trial			
		0	1	2	3
Number of experimental arms continuing to 2 nd stage	0	40.5%	4.3%	1.0%	0.4%
	1	26.8%	45.8%	6.4%	2.3%
	2	19.3%	30.7%	58.8%	9.2%
	3	13.4%	19.2%	33.8%	88.1%

Detected at least one truly effective treatment ('power')	-	87.3%	96.2%	98.3%
At least one ineffective treatment found significant ('type I error')	3.7%	2.6%	1.3%	-

Results are column %, based on 10,000 simulations for each of the four scenarios (number of effective treatments at start).

Table 3 Expected trial duration under different assumptions.

Scenario	Expected time of stage 1 analysis (years)	Expected time of stage 2 analysis (years)	% of total participants by stage 1 analysis ^a
Base-case ^b	3.4	6.1	58%
Recruitment 20% slower	3.7	6.5	51%
Recruitment 20% faster	3.3	5.7	66%
2 experimental arms in stage 2	3.4	6.2	58%
3 experimental arms in stage 2	3.4	6.3	58%
45% progression rate at 3 years	3.4	6.6	58%
55% progression rate at 3 years	3.4	5.7	58%

^a Number of participants recruited in trial at the time of the interim analysis / total trial size for arms continuing to stage 2.

^b Assumed recruitment rate of 40 participants per month during stage 1, and 50 per month during stage 2, 50% disability progression rate at 3 years, and one experimental arm continuing into stage 2.

FIGURES

Figure 1. Schematic representation of the MAMS trial comparing three experimental arms to standard of care in two stages (A) and traditional two-arm phase II and III clinical trials (B).




Figure 2. Predicted standard deviation of atrophy rate for varying follow-up length, based on modelling of MS-STAT1 and ASCEND trial data^{20,35}.




Figure 3. Association between treatment effect on brain atrophy and disability progression in PMS trials. The size of each circle is proportional to the trial size.

